## Edgar Filing: Rosenberg Ellen - Form 4

Rosenberg Ellen Form 4 April 15, 2019				
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction	NERSHIP OFNumber:3235-0287Number:January 31,Expires:2005Estimated average burden hours per response0.5ge Act of 1934,0.5			
1(b). (Print or Type Responses)				
1. Name and Address of Reporting Person <u>*</u> Rosenberg Ellen	2. Issuer Name <b>and</b> Ticker or Trading Symbol AMICUS THERAPEUTICS, INC. [FOLD]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)		
(Last) (First) (Middle) C/O AMICUS THERAPEUTICS, 1 CEDAR BROOK DRIVE	3. Date of Earliest Transaction (Month/Day/Year) 04/11/2019	Director 10% Owner X Officer (give title Other (specify below) below) Chief Legal Officer		
(Street)	4. If Amendment, Date Original Filed(Month/Day/Year)	<ul> <li>6. Individual or Joint/Group Filing(Check</li> <li>Applicable Line)</li> <li>_X_Form filed by One Reporting Person</li> <li>Form filed by More than One Reporting</li> </ul>		
CRANBURY, NJ 08512		Person		
(City)(State)(Zip)1.Title of Security2. Transaction Date (Month/Day/Year)2A. Dee Execution Execution any (Month/(Instr. 3)any (Month/	emed 3. 4. Securities Acquired	Amount of Securities6. Ownership Form: Direct7. Nature of Indirect5. Amount of Securities6. Ownership Form: Direct7. Nature of IndirectBeneficially Owned(D) orBeneficial OwnershipOwnedIndirect (I) Indirect (I)Ownership (Instr. 4)Following Transaction(s) (Instr. 3 and 4)(Instr. 4)		
Common Stock (1) 04/11/2019	A 20,579 A \$0	154,127 D		
Common Stock		15,000 I By Spouse		

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

## Edgar Filing: Rosenberg Ellen - Form 4

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	4. Transact Code (Instr. 8)	5. ionNumber of Derivativ Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	;	ate	Secur	int of rlying	8. Price of Derivative Security (Instr. 5)	9. Nu Deriv Secur Bene Owne Follo Repo Trans (Instr
			Code V	′ (A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		

## **Reporting Owners**

<b>Reporting Owner Name / Address</b>	Relationships					
reporting of the reader that ess	Director	10% Owner	Officer	Other		
Rosenberg Ellen C/O AMICUS THERAPEUTICS 1 CEDAR BROOK DRIVE CRANBURY, NJ 08512			Chief Legal Officer			
Signatures						
Christian Formica, Attorney-in-Fact	04	/15/2019				

<u>\*\*</u>Signature of Reporting Person

Date

## **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- Granted in the form of Restricted Stock Units for the achievement of the 2017 PRSU clinical goal. Each Restricted Stock Unit represents(1) a contingent right to receive one share of Amicus common stock. The Restricted Stock Units will vest on December 31, 2019, subject to the reporting person's continued service with the Company.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.